Ilsung Is Co., Ltd. (KRX:003120)

South Korea · Delayed Price · Currency is KRW

20,500

-250 (-1.20%)

At close: Aug 21, 2026

-6.39% (1Y)

Market Cap	142.86B -6.4%
Revenue (ttm)	65.22B -5.2%
Net Income	5.54B -52.2%
EPS	n/a
Shares Out	6.97M
PE Ratio	25.78
Forward PE	n/a
Dividend	1,200.00 (5.83%)
Ex-Dividend Date	Dec 29, 2025

Volume	4,643
Open	20,600
Previous Close	20,750
Day's Range	20,200 - 21,000
52-Week Range	17,120 - 29,300
Beta	-0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Ilsung Is

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular sys... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1954

Country South Korea

Stock Exchange Korea Stock Exchange

Ticker Symbol 003120

Full Company Profile

Financial Performance

In 2025, Ilsung Is's revenue was 64.29 billion, a decrease of -6.85% compared to the previous year's 69.02 billion. Earnings were 1.17 billion, a decrease of -91.10%.

Financial Statements